WA-REMOTE-MEDICAL-INTL
15.7.2020 15:02:12 CEST | Business Wire | Press release
Remote Medical International, a global leader in workplace health and safety services for Fortune 100 corporations and government services prime contractors, announced it completed its acquisition of SSI Group on July 1. Based in the United Kingdom, SSI specializes in emergency response medical services for the oil and gas and renewable energy sectors, global risk management, and international safety.
“This acquisition is part of our strategy to aggressively expand into new markets, notably renewable energy, broaden our offerings to include risk management, and build on our leading COVID-19 services,” said Wayne Wager, CEO of Remote Medical International. “The complementary nature of our businesses adds to our ability to design bespoke solutions for our clients that save lives and improve the health of workers in diverse job sites around the world.”
Remote Medical International will leverage SSI’s years of work to provide medical and technical support for offshore wind farm and other renewable energy construction in the North Sea and North America and expand its work with large corporations working in remote and challenging locations globally. The combined expertise will produce a comprehensive range of COVID-19 medical services and solutions for businesses seeking to create safe back-to-work situations under one Remote Medical International offering.
The combined companies will deliver unparalleled quality by setting the highest standards for medical and safety personnel and clinical governance. Customers will benefit from the companies’ vast experience in offering workplace health and safety and risk management services to more than 120 countries across the globe.
“We are delighted to join the Remote Medical International team and believe that together our companies will deliver greater value to our customers through our common values of quality, agility, responsiveness, and collaboration,” said Duncan Higham, Founder and Managing Director of SSI. ”We share a passion for delivering unparalleled services and a vision of being the best remote medical provider on land and at sea.”
Mr. Higham has been named Remote Medical International’s vice president global strategy, reporting directly to Wayne Wager, CEO of Remote Medical International. Julian Rawles, formerly SSI’s commercial director, will serve as the managing director of Remote Medical International UK reporting to Paul Budak, chief operating officer. No other changes in either organization are anticipated. The terms of the acquisition were not disclosed. Visit the company’s website, https://remotemedical.com/ for more information.
About Remote Medical International
Headquartered in Seattle, Washington, Remote Medical International saves lives and protects the health and wellbeing of workers in diverse job sites from remote pipeline installations to offshore wind and maritime operations. The company has been recognized six times by Inc. 5000 as one of the fastest-growing companies in the United States and works with Fortune 100 corporations and government services prime contractors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200715005453/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom